Matthew Ward, MD
Radiation Oncology · Charlotte, NCNPI 1043570948
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Bayer at 58.5% of the total. Reporting peaked in 2021 at $1,463 and has fallen 59.9% since, to $586 in 2025.
Across 13 payments — averaging $208.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$2K
- Teleflex LLC$350
- Siemens Medical Solutions USA, Inc.$341
- Varian Medical Systems, Inc.$183
- Elekta, Inc.$142
- Novartis$65
- plus $45 from 2 others
What the payments were for
- Consulting fees$1,46354%
- Speaking & faculty fees$35013%
- Food & beverage$90133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $1,587 |
| Teleflex LLC | 1 | $350 |
| Siemens Medical Solutions USA, Inc. | 3 | $341 |
| Varian Medical Systems, Inc. | 2 | $183 |
| Elekta, Inc. | 2 | $142 |
| Novartis | 1 | $65 |
| Boston Scientific | 1 | $29 |
| Palette Life Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofigo$1,587
- Barrigel$350
- ELEKTA MEDICAL LINEAR ACCELERATOR$123
- TrueBeam$104
How this compares
$2,713 in reported general payments places this provider in the 80th percentile of 199 radiation oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 58 | $649 |
| Cefpodoxime Proxetil | 41 | $626 |
| Chlorhexidine Gluconate | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Charlotte
- John HeinzerlingCharlotte$29K
- Stuart BurriCharlotte$17K
- Michael LecompteCharlotte$9K
- Roshan PrabhuCharlotte$6K
- Andrew WangChapel Hill$118K
- Volker StieberWinston Salem$99K
- Lewis SulmanDurham$54K
- Michael PapagikosWilmington$51K
- William LeeDurham$37K
- Matthew ManningGreensboro$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.